# Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

> **NCT00303719** · PHASE2 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 342 (actual)

## Conditions studied

- Kidney Cancer
- Leukemia
- Lymphoma
- Multiple Myeloma
- Plasma Cell Neoplasm
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **DRUG:** cyclophosphamide
- **DRUG:** cyclosporine
- **DRUG:** fludarabine
- **DRUG:** mycophenolate mofetil
- **PROCEDURE:** stem cell transplantation
- **RADIATION:** total body irradiation
- **DRUG:** filgrastim

## Key facts

- **NCT ID:** NCT00303719
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-03-26
- **Primary completion:** 2019-05-08
- **Final completion:** 2019-05-08
- **Target enrollment:** 342 (ACTUAL)
- **Why stopped:** IRB Study Closure
- **Last updated:** 2020-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303719, "Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT00303719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*